Rompun: Product Information (Page 2 of 2)


Human Safety: Not for human use. Keep out of reach of children.

  • Strictly avoid self-injection, oral intake and any contact with skin, eyes or mucosa.
  • In the case of accidental contact wash exposed skin or eyes abundantly with water. If symptoms occur, seek medical advice.
  • In the case of accidental oral intake or self-injection, seek the advice of a physician and show the package insert but DO NOT DRIVE.
  • If pregnant women handle the product, special caution should be observed not to self-inject as uterine contractions and decreased fetal blood pressure may occur after accidental systemic exposure.
  • Users with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid any exposure to this product.
  • Caution should be exercised when handling sedated animals. Handling or any other sudden stimuli, including noise, may cause a defense reaction in an animal that appears to be heavily sedated.

Note to physician: Xylazine is an alpha2-adrenergic agonist with sedative, some analgesic and muscle relaxant properties. Symptoms after absorption may include dose-dependent respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycemia. Ventricular arrhythmias have also been reported.

The safety data sheet (SDS) contains more detailed occupational safety information. To report adverse reactions in users or to obtain a copy of the SDS for this product call Dechra at 1-(866)-933-2472.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or

Animal safety: This drug should not be administered to domestic food-producing animals. Do not use in horses intended for human consumption.

In Cervidae , occasional capture-associated deaths occur. Clinical trials reveal a mortality rate of approximately 3.5% attendant with the administration of xylazine.

HOW SUPPLIED: Rompun (xylazine injection) 100 mg/mL Injection for intravenous or intramuscular use is available in 50 mL multiple dose vials.

STORAGE: Do not Freeze. Store at 20°C — 25°C (68°F — 77°F), excursions permitted up to 40°C (104°F).


  1. Detweiler, D.K.: “The Diagnosis and Significance of Cardiac Arrhythmias.” Progress In Equine Practice. Edited by E.J. Catcott and J.F. Smithcors.American Veterinary Publications, Inc., Santa Barbara. California and Wheaton, Illinois, (1966), 280-281.
  2. Glazier, D.B.: “Atrioventricular Heart Block.” Irish Vet. J, Vol. 12, (1958), 194-198.
  3. Holmes, J.R., Alps, B.J.: “Observations on Partial Atrioventricular Heart Block in the Horse.” Can. Vet. J., Vol. 7, No. 12, (1966), 280-290.
  4. Smetzer, D.L., Smith, C.R., Senta, T: “Second Degree Atrioventricular Block in the Horse.” Am. J. Vet. Res., Vol. 30, No. 6, (1969), 933-946.

Manufactured for:
Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211 USA

Made in Latvia

Approved by FDA under NADA # 047-956

1000001151 B2L2

Rompun® is a registered trademark of Dechra Limited.
© 2022 Dechra Limited

Rev. January 2022


(xylazine injection)
100 mg/mL

Sedative and Analgesic
For Use In Horses
and Cervidae Only

CONTAINS PER ML: Xylazine (base
equivalent) 100 mg (present as the
hydrochloride) with methylparaben
0.9 mg; propylparaben 0.1 mg; water for
injection; citric acid and sodium citrate for
pH adjustment to 5.5 ± 0.3.

Approved by FDA under NADA # 047-956

Net Contents:50 mL


(click image for full-size original)
ROMPUN xylazine injection, solution
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:17033-099
Route of Administration INTRAMUSCULAR, INTRAVASCULAR DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
# Item Code Package Description Multilevel Packaging
1 NDC:17033-099-05 1 BOTTLE in 1 CARTON contains a BOTTLE
1 50 mL in 1 BOTTLE This package is contained within the CARTON (17033-099-05)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NADA NADA047956 05/07/2014
Labeler — Dechra Vet Products, LLC (362142734)

Revised: 06/2022 Dechra Vet Products, LLC

Page 2 of 2 1 2 provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2022. All Rights Reserved.